YU8201A - Jedinjenja 2-supstituisan-1-piperidil benzimidazola kao orl1-receptor agonisti - Google Patents

Jedinjenja 2-supstituisan-1-piperidil benzimidazola kao orl1-receptor agonisti

Info

Publication number
YU8201A
YU8201A YU8201A YU8201A YU8201A YU 8201 A YU8201 A YU 8201A YU 8201 A YU8201 A YU 8201A YU 8201 A YU8201 A YU 8201A YU 8201 A YU8201 A YU 8201A
Authority
YU
Yugoslavia
Prior art keywords
alkyl
substituted
orl1
aromatic
unsubstituted
Prior art date
Application number
YU8201A
Other languages
English (en)
Inventor
Fumitaka Ito
Hirohide Noguchi
Hiroshi Kondo
Original Assignee
Pfizer Inc.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Pfizer Inc. filed Critical Pfizer Inc.
Publication of YU8201A publication Critical patent/YU8201A/sh

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P23/00—Anaesthetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16—Anti-Parkinson drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/20—Hypnotics; Sedatives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/22—Anxiolytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/12—Drugs for disorders of the metabolism for electrolyte homeostasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P39/00—General protective or antinoxious agents
    • A61P39/02—Antidotes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/12—Antihypertensives
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D211/00—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings
    • C07D211/04—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D211/06—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members
    • C07D211/36—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D211/56—Nitrogen atoms
    • C07D211/58—Nitrogen atoms attached in position 4
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings

Landscapes

  • Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Engineering & Computer Science (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Psychiatry (AREA)
  • Anesthesiology (AREA)
  • Toxicology (AREA)
  • Psychology (AREA)
  • Rheumatology (AREA)
  • Pain & Pain Management (AREA)
  • Cardiology (AREA)
  • Hospice & Palliative Care (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Addiction (AREA)
  • Diabetes (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Hydrogenated Pyridines (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

Jedinjenje formule (I) ili njegova farmaceutski prihvatljiva so, gde R je nesupstituisan, mono-di- ili tri-supstituisan (C3-C11) cikloalkil ili (C3-C11) cikloalkenil ili slicno; A je nesupstituisan (C1-C7) alkil ili (C2-C5) alkenil, ili nesupstituisan, mono- di ili tri-supstituisan aril, ili aromaticni-heterociklik ili slicno; Y je vodonik, halo, amino ili merkapto, ili nesupstituisan, mono-, di- ili tri-supstituisan (C1-C10) alkil-M-, (C3-C7) cikloalkil-M, (C2-C6) alkenil-M-, (C1-C4) alkil-NH-((C1-C4) alkil)-M-, di((C1-C4) alkil-N-((C1-C4) alkil-M-, aril-M-, aromaticni ili nearomaticni heterociklik-M-, aril-(C1-C5) alkil-M ili aromaticni ili nearomaticni heterociklik-(C1-C5) alkil-M-, gde M je kovalentna veza O, S, NH ili slicno; Z1, Z2, Z3 i Z4 su vodonik ili slicno; ima aktivnost ORL1-receptor agonista, i korisno je kao analgetici ili slicno kod subjekata sisara.
YU8201A 1998-08-06 1999-07-05 Jedinjenja 2-supstituisan-1-piperidil benzimidazola kao orl1-receptor agonisti YU8201A (sh)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
IBPCT/IB98/01206 1998-08-06

Publications (1)

Publication Number Publication Date
YU8201A true YU8201A (sh) 2003-07-07

Family

ID=11004738

Family Applications (1)

Application Number Title Priority Date Filing Date
YU8201A YU8201A (sh) 1998-08-06 1999-07-05 Jedinjenja 2-supstituisan-1-piperidil benzimidazola kao orl1-receptor agonisti

Country Status (44)

Country Link
US (1) US6172067B1 (sh)
EP (1) EP1102762B1 (sh)
JP (1) JP3367945B2 (sh)
CN (1) CN1317968A (sh)
AP (1) AP2001002063A0 (sh)
AR (1) AR018686A1 (sh)
AT (1) ATE227716T1 (sh)
AU (1) AU749166B2 (sh)
BG (1) BG105301A (sh)
BR (1) BR9912778A (sh)
CA (1) CA2339621C (sh)
CZ (1) CZ2001397A3 (sh)
DE (1) DE69903953T2 (sh)
DK (1) DK1102762T3 (sh)
EA (1) EA200100104A1 (sh)
EE (1) EE200100075A (sh)
ES (1) ES2185357T3 (sh)
GE (1) GEP20033000B (sh)
GT (1) GT199900125A (sh)
HK (1) HK1040188A1 (sh)
HN (1) HN1999000105A (sh)
HR (1) HRP20010089B1 (sh)
HU (1) HUP0103567A3 (sh)
ID (1) ID27212A (sh)
IL (1) IL141029A0 (sh)
IS (1) IS5812A (sh)
MA (1) MA26659A1 (sh)
NO (1) NO20010603L (sh)
NZ (1) NZ509299A (sh)
OA (1) OA11590A (sh)
PA (1) PA8477701A1 (sh)
PE (1) PE20000868A1 (sh)
PL (1) PL346211A1 (sh)
PT (1) PT1102762E (sh)
SI (1) SI1102762T1 (sh)
SK (1) SK1602001A3 (sh)
SV (1) SV1999000099A (sh)
TN (1) TNSN99142A1 (sh)
TR (1) TR200100403T2 (sh)
TW (1) TW513424B (sh)
UY (1) UY25659A1 (sh)
WO (1) WO2000008013A2 (sh)
YU (1) YU8201A (sh)
ZA (1) ZA200100900B (sh)

Families Citing this family (51)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6340681B1 (en) * 1999-07-16 2002-01-22 Pfizer Inc 2-benzimidazolylamine compounds as ORL-1-receptor agonists
SE9902987D0 (sv) 1999-08-24 1999-08-24 Astra Pharma Prod Novel compounds
SE9903544D0 (sv) 1999-10-01 1999-10-01 Astra Pharma Prod Novel compounds
DE60023100T2 (de) * 2000-01-05 2006-07-06 Pfizer Inc. Benzimidazol-Verbindungen zur Verwendung als ORL1-Rezeptor-Antagonisten
GB2359078A (en) 2000-02-11 2001-08-15 Astrazeneca Uk Ltd Pharmaceutically active pyrimidine derivatives
GB2359081A (en) 2000-02-11 2001-08-15 Astrazeneca Uk Ltd Pharmaceutically active thiazolopyrimidines
GB2359551A (en) 2000-02-23 2001-08-29 Astrazeneca Uk Ltd Pharmaceutically active pyrimidine derivatives
GB0005642D0 (en) 2000-03-10 2000-05-03 Astrazeneca Uk Ltd Chemical compounds
SE0003828D0 (sv) 2000-10-20 2000-10-20 Astrazeneca Ab Novel compounds
AU2002224038B2 (en) * 2000-11-15 2006-03-09 Banyu Pharmaceutical Co., Ltd. Benzimidazole derivatives
GB0104050D0 (en) 2001-02-19 2001-04-04 Astrazeneca Ab Chemical compounds
GB0107228D0 (en) 2001-03-22 2001-05-16 Astrazeneca Ab Chemical compounds
SE0101322D0 (sv) 2001-04-12 2001-04-12 Astrazeneca Ab Novel compounds
DK1385514T5 (da) 2001-04-18 2009-03-09 Euro Celtique Sa Spiroinden- og spiroindanforbindelser
DK1385515T3 (da) 2001-04-18 2008-10-27 Euro Celtique Sa Spiropyrazole forbindelser
EP1997818A3 (en) * 2001-04-18 2009-04-08 Euro-Celtique S.A. Quinolinone derivatives and their use to treat pain
BR0209129A (pt) * 2001-04-18 2005-12-20 Euro Celtique Sa Compostos, composições farmacêuticas, métodos para tratamento de dores, métodos para modulação de uma resposta farmacológica e usos de compostos
PT1975164E (pt) * 2001-04-18 2010-04-20 Euro Celtique Sa Compostos de octa-hidrobenzimidazolona utilizados como analgésicos
EP1406629A1 (en) * 2001-07-02 2004-04-14 Omeros Corporation Method for inducing analgesia comprising administration alternatively of an opioid receptor agonist and an opioid receptor like receptor 1 agonist for and an implantable infusion pump
US20030040479A1 (en) * 2001-07-02 2003-02-27 Omeros Corporation Rotational intrathecal analgesia method and device
SE0102716D0 (sv) * 2001-08-14 2001-08-14 Astrazeneca Ab Novel compounds
SE0103818D0 (sv) 2001-11-15 2001-11-15 Astrazeneca Ab Chemical compounds
AU2002360561A1 (en) * 2001-12-11 2003-06-23 Sepracor, Inc. 4-substituted piperidines, and methods of use thereof
PT1491212E (pt) 2002-03-29 2012-11-16 Mitsubishi Tanabe Pharma Corp Medicamento para distúrbios de sono
GB0221828D0 (en) 2002-09-20 2002-10-30 Astrazeneca Ab Novel compound
GB0221829D0 (en) * 2002-09-20 2002-10-30 Astrazeneca Ab Novel compound
DE10252666A1 (de) 2002-11-11 2004-08-05 Grünenthal GmbH N-Piperidyl-cyclohexan-Derivate
DE10252665A1 (de) * 2002-11-11 2004-06-03 Grünenthal GmbH 4-Aminomethyl-1-aryl-cyclohexylamin-Derivate
SE0301369D0 (sv) 2003-05-09 2003-05-09 Astrazeneca Ab Chemical compounds
GB0315203D0 (en) * 2003-06-28 2003-08-06 Celltech R&D Ltd Chemical compounds
SA04250305B1 (ar) 2003-09-25 2008-06-02 سولفاي فارماسوتيكالز بي . في مشتقات بنزيميدازولون cenzimidazolone وكينازولينون quinazolinone كمساعادات على مستقبلات ORL1 البشرية
GB0328243D0 (en) 2003-12-05 2004-01-07 Astrazeneca Ab Methods
US20050228023A1 (en) * 2003-12-19 2005-10-13 Sri International Agonist and antagonist ligands of the nociceptin receptor
CA2583326A1 (en) * 2004-10-08 2006-04-13 Takeda Pharmaceutical Company Limited Receptor function regulating agent
WO2006074991A1 (en) 2005-01-11 2006-07-20 Neurosearch A/S Novel 2-amino benzimidazole derivatives and their use as modulators of small-conductance calcium-activated potassium channels
WO2008003667A2 (en) * 2006-07-03 2008-01-10 Neurosearch A/S Combinations of monoamine reuptake inhibitors and potassium channel activators
KR101370434B1 (ko) 2007-01-16 2014-03-06 시오노기세이야쿠가부시키가이샤 Orl-1 리간드로서의 헤테로시클릭-치환 피페리딘
KR20140139125A (ko) * 2007-08-31 2014-12-04 퍼듀 퍼머 엘피 치환-퀴녹살린-형 피페리딘 화합물 및 그의 용도
US8119661B2 (en) * 2007-09-11 2012-02-21 Astrazeneca Ab Piperidine derivatives and their use as muscarinic receptor modulators
HRP20120841T4 (hr) 2008-07-21 2015-07-03 Purdue Pharma L.P. Premošteni piperidinski spojevi substituiranog kinoksalin-tipa i njihova uporaba
MX2013001313A (es) 2010-08-05 2013-06-13 Amgen Inc Compuestos de bencimidazol y azabencimidazol que inhiben la cinasa del linfoma anaplasico.
US9169203B2 (en) 2012-01-06 2015-10-27 Novus International, Inc. Sulfoxide-based surfactants
HRP20181671T1 (hr) 2012-02-09 2018-12-14 Novus International, Inc. Heteroatom koji sadrži cikličke dimere
JO3300B1 (ar) 2012-06-06 2018-09-16 Novartis Ag مركبات وتركيبات لتعديل نشاط egfr
CA2878617A1 (en) 2012-07-12 2014-01-16 Houston Stephen Smith Matrix and layer compositions for protection of bioactives
US9085561B2 (en) * 2012-07-30 2015-07-21 Purdue Pharma L.P. Cyclic urea- or lactam-substituted quinoxaline-type piperidines as ORL-1 modulators
WO2014102594A2 (en) * 2012-12-27 2014-07-03 Purdue Pharma L.P. Substituted benzimidazole-type piperidine compounds and uses thereof
US9656994B2 (en) 2013-03-22 2017-05-23 The Scripps Research Institute Substituted benzimidazoles as nociceptin receptor modulators
CA3175724C (en) * 2014-03-20 2024-01-09 Capella Therapeutics, Inc. Benzimidazole derivatives, and pharmaceutical compositions and methods of use thereof
US10227551B2 (en) 2015-11-12 2019-03-12 Novus International, Inc. Sulfur-containing compounds as solvents
US10584306B2 (en) 2017-08-11 2020-03-10 Board Of Regents Of The University Of Oklahoma Surfactant microemulsions

Family Cites Families (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3318900A (en) * 1964-05-06 1967-05-09 Janssen Pharmaceutica Nv Derivatives of benzimidazolinyl piperidine
JPS5297978A (en) * 1976-06-02 1977-08-17 Yoshitomi Pharmaceut Ind Ltd Preparation of alicyclic derivatives
US5821219A (en) 1995-08-11 1998-10-13 Oregon Health Sciences University Opioid antagonists and methods of their use
EP0845034B1 (en) 1995-08-15 2003-03-05 Euroscreen S.A. peptide having pronociceptive properties
US5866346A (en) 1995-09-27 1999-02-02 Indiana Unversity Foundation Methods of using dynorphins as ligands for XOR1 receptor
US6180649B1 (en) * 1996-04-19 2001-01-30 Nerosearch A/S 1-(4-piperidyl)-benzimidazoles having neurotrophic activity
EP0813065A3 (en) 1996-06-13 1998-07-22 F. Hoffmann-La Roche Ag Modulation of LC132 (opioid-like) receptor function
EP0829481A1 (en) * 1996-09-16 1998-03-18 Pfizer Inc. Morphinan hydroxamic acid compounds
US5718912A (en) * 1996-10-28 1998-02-17 Merck & Co., Inc. Muscarine agonists
US6258825B1 (en) 1997-05-30 2001-07-10 Banyu Pharmaceutical Co., Ltd. 2-oxoimidazole derivatives
AU8334298A (en) 1997-07-15 1999-02-10 Novo Nordisk A/S Nociceptin analogues
US5929035A (en) 1998-04-14 1999-07-27 Regents Of The University Of Michigan Methods of treating intestinal disorders
ID29137A (id) 1998-07-27 2001-08-02 Schering Corp Ligan-ligan afinitas tinggi untuk reseptor nosiseptin orl-1

Also Published As

Publication number Publication date
PA8477701A1 (es) 2000-09-29
EE200100075A (et) 2002-06-17
WO2000008013A2 (en) 2000-02-17
OA11590A (en) 2004-08-18
JP3367945B2 (ja) 2003-01-20
HUP0103567A3 (en) 2003-01-28
AP2001002063A0 (en) 2001-03-31
ZA200100900B (en) 2002-08-28
PE20000868A1 (es) 2000-08-31
WO2000008013A3 (en) 2000-03-23
NO20010603L (no) 2001-04-05
PT1102762E (pt) 2003-02-28
CA2339621A1 (en) 2000-02-17
NZ509299A (en) 2003-05-30
AU4385999A (en) 2000-02-28
TR200100403T2 (tr) 2001-07-23
UY25659A1 (es) 2000-02-23
US6172067B1 (en) 2001-01-09
ES2185357T3 (es) 2003-04-16
BG105301A (en) 2001-12-29
SK1602001A3 (en) 2002-09-10
JP2002522431A (ja) 2002-07-23
BR9912778A (pt) 2001-09-25
SV1999000099A (es) 2000-09-05
DE69903953T2 (de) 2003-03-27
EP1102762B1 (en) 2002-11-13
HRP20010089A2 (en) 2002-02-28
HRP20010089B1 (en) 2003-04-30
TNSN99142A1 (fr) 2005-11-10
IS5812A (is) 2001-01-16
NO20010603D0 (no) 2001-02-05
DK1102762T3 (da) 2002-12-16
SI1102762T1 (en) 2003-04-30
MA26659A1 (fr) 2004-12-20
CN1317968A (zh) 2001-10-17
AU749166B2 (en) 2002-06-20
CA2339621C (en) 2005-04-05
CZ2001397A3 (cs) 2002-05-15
GEP20033000B (en) 2003-06-25
HN1999000105A (es) 2000-11-11
AR018686A1 (es) 2001-11-28
PL346211A1 (en) 2002-01-28
EA200100104A1 (ru) 2001-08-27
HK1040188A1 (zh) 2002-05-31
IL141029A0 (en) 2002-02-10
ATE227716T1 (de) 2002-11-15
EP1102762A2 (en) 2001-05-30
TW513424B (en) 2002-12-11
ID27212A (id) 2001-03-08
DE69903953D1 (de) 2002-12-19
HUP0103567A2 (hu) 2002-02-28
GT199900125A (es) 2001-01-27

Similar Documents

Publication Publication Date Title
AP2001002063A0 (en) 2-substituted-1-piperidyl benzimidazole compounds as orl1-receptor agonists.
CA2330092A1 (en) Benzimidazole compounds as orl1-receptor agonists
GR3025485T3 (en) Antiatherosclerotic and antithrombotic 1-benzopyran-4-ones and 2-amino-1,3-benzoxazine-4-ones
KR910004582A (ko) 티아졸 유도체, 이의 제조방법 및 이를 함유하는 약학조성물
CO5221089A1 (es) Combinaciones de un derivado de fluorbenzotiazol y folpet con actividad fungicida
ATE292634T1 (de) Inhibitoren der alpha-l beta-2 vermittelten zelladhäsion
CA2290992A1 (en) (imidazol-5-yl)methyl-2-quinolinone derivatives as inhibitors of smooth muscle cell proliferation
AP2000001801A0 (en) Chemical compounds.
PL335518A1 (en) 1,8-cycled n- or c-bound imidazole substituted derivatives of quinolynone inhibiting farnesil transferase
NZ528676A (en) Use of bisphosphonates in the treatment of bone metastases associated with prostate cancer
GB9919588D0 (en) Fungicidal compounds
DK0749424T3 (da) Naphthalenderivater som prostaglandin-I2-agonister
GR3021804T3 (en) Indole derivatives as 5-h1-like agonists for use in migraine
TR200103683T2 (tr) Indol türevleri ve bu türevlerin diğer uygulamaların yanısıra osteoporoz tedavisinde kullanımı
HUP9800809A2 (hu) Ciklusos peptid gombaellenes hatóanyagok
MY141292A (en) Aminobenzimidazoles and benzimidazoles as inhibitors of respiratory syncytial virus replication
IL132773A0 (en) Guanidinylation reagents
AR044175A1 (es) Compuestos de cefemo
GB1530568A (en) 1-azolyl-4-hydroxy-butane derivatives and their use as fungicides and bactericides
ES2143389B1 (es) Solucion cutanea para deposito directo destinado a la eliminacion de parasitos en bovinos y ovinos.
NZ504614A (en) Echinocandin derivatives and application as anti-fungal agents
HUP0002242A2 (hu) Alfa-2 adrenoceptor agonistaként alkalmazható 5-[(imidazolinil)-amino]-benzoimidazol-származékok
AP9901637A0 (en) Crystalline hydrated sodium salt of (E)-4,6-dichloro-3-(2-oxo-1-phenylpyrrolidin-3-ylidene methyl)-1H-indole-2-carboxylic acid.
ECSP993046A (es) Compuesto de 1 -piperidil benzoimidazol 2 - sustituidos como agonistas de receptores orl1
MY125808A (en) Il-5 inhibiting 6-azauracil derivatives